Company intelligence / Profile preview

Concentrx Pharmaceuticals, Inc.

Durham, North Carolina, United Statesconcentrxpharma.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Concentrx Pharmaceuticals is developing the Halix™ Unit Dose Disposable - Dry Powder Inhaler platform for respiratory conditions. The product was reported to be ready for clinical trials manufacturing in mid-2016 with FDA approval expected in 2018, though current status is unclear from the search results.

Therapeutic areas: Pulmonology
Modalities: Dry powder inhalers
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

albuterol

Pre-clinical

Indications: Asthma, Chronic obstructive pulmonary disease

Beyond the preview

Go deeper on Concentrx Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Concentrx Pharmaceuticals, Inc..

Explore the full profile